Abstract
Influenza has a long history of causing morbidity and mortality in the human population through routine seasonal spread and global pandemics. The high mutation rate of the RNA genome of the influenza virus, combined with assortment of its multiple genomic segments, promote antigenic diversity and new subtypes, allowing the virus to evade vaccines and become resistant to antiviral drugs. There is thus a continuing need for new anti-influenza therapy using novel targets and creative strategies. In this review, we summarize prospective future therapeutic regimens based on recent molecular and genomic discoveries. © 2012 Barik; licensee BioMed Central Ltd.
| Original language | English |
|---|---|
| Article number | 104 |
| Journal | BMC Medicine |
| Volume | 10 |
| DOIs | |
| State | Published - Sep 13 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cathelicidin
- NSAID
- defensin
- hemagglutinin
- influenza
- neuraminidase
- oseltamivir
- siRNA
- zanamivir
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver